ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.90
      0.14%
      Bitcoin
      65,055.90
      -0.13%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Atara Biotherapeutics Inc (ATRA)

      7. Atara Biotherapeutics Inc (ATRA) News

      ATRA

      Atara Biotherapeutics (ATRA)

      Atara Biotherapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ATRA
      DateTimeSourceHeadlineSymbolCompany
      12/19/20227:00AMBusiness WireAtara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDNASDAQ:ATRAAtara Biotherapeutics Inc
      12/16/20225:43PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ATRAAtara Biotherapeutics Inc
      12/15/20224:01PMBusiness WireAtara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
      12/12/202210:00AMBusiness WireAtara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
      12/02/20224:01PMBusiness WireAtara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
      11/23/20228:00AMBusiness WireAtara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
      11/22/20221:15PMTipRanksMizuho Securities Sticks to Its Buy Rating for Atara Biotherapeutics (ATRA)NASDAQ:ATRAAtara Biotherapeutics Inc
      11/09/20224:01PMBusiness WireAtara Biotherapeutics to Participate at the Stifel Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
      11/08/202210:45PMTipRanksMizuho Securities Keeps Their Buy Rating on Atara Biotherapeutics (ATRA)NASDAQ:ATRAAtara Biotherapeutics Inc
      11/08/20224:22PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ATRAAtara Biotherapeutics Inc
      11/08/20224:16PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRAAtara Biotherapeutics Inc
      11/08/20224:01PMBusiness WireAtara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
      11/04/20224:01PMBusiness WireAtara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
      11/01/20224:05PMBusiness WireAtara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022NASDAQ:ATRAAtara Biotherapeutics Inc
      10/26/20222:01AMBusiness WireAtara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022NASDAQ:ATRAAtara Biotherapeutics Inc
      10/17/20224:15AMTipRanksMizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)NASDAQ:ATRAAtara Biotherapeutics Inc
      10/14/20228:10AMPR Newswire (US)CHMP Recommends Approval of Atara Biotherapeutics' EbvalloTM (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative DiseaseNASDAQ:ATRAAtara Biotherapeutics Inc
      10/14/20227:08AMBusiness WireCHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative DiseaseNASDAQ:ATRAAtara Biotherapeutics Inc
      10/10/20224:01PMBusiness WireAtara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
      09/28/20224:01PMBusiness WireAtara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre FabreNASDAQ:ATRAAtara Biotherapeutics Inc
      08/31/20224:01PMBusiness WireAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
      08/18/20226:24PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      08/18/20226:22PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      08/18/20226:21PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      08/18/20226:15AMTipRanksH.C. Wainwright Reaffirms Their Buy Rating on Atara Biotherapeutics (ATRA)NASDAQ:ATRAAtara Biotherapeutics Inc
      08/11/202210:11PMTipRanksStifel Nicolaus Sticks to Their Hold Rating for Atara Biotherapeutics (ATRA)NASDAQ:ATRAAtara Biotherapeutics Inc
      08/08/20229:25PMTipRanksMizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)NASDAQ:ATRAAtara Biotherapeutics Inc
      08/08/20224:01PMBusiness WireAtara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy UpdateNASDAQ:ATRAAtara Biotherapeutics Inc
      08/04/20224:01PMBusiness WireAtara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
      08/03/20224:01PMBusiness WireAtara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ATRA